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Estimating the tolerance of brachial
plexus to hypofractionated stereotactic body
radiotherapy: a modelling‑based approach
from clinical experience
Irina Kapitanova1, Sharmi Biswas2, Sabrina Divekar3, Eric J. Kemmerer4, Robert A. Rostock4, Kenneth M. Forster4,
Rachel J. Grimm5, Carla J. Scofield4, Jimm Grimm4,6* , Bahman Emami7 and Anand Mahadevan4

Abstract
Background: Brachial plexopathy is a potentially serious complication from stereotactic body radiation therapy
(SBRT) that has not been widely studied. Therefore, we compared datasets from two different institutions and generated a brachial plexus dose–response model, to quantify what dose constraints would be needed to minimize the
effect on normal tissue while still enabling potent therapy for the tumor.
Methods: Two published SBRT datasets were pooled and modeled from patients at Indiana University and the Richard L. Roudebush Veterans Administration Medical Center from 1998 to 2007, as well as the Karolinska Institute from
2008 to 2013. All patients in both studies were treated with SBRT for apically located lung tumors localized superior
to the aortic arch. Toxicities were graded according to Common Terminology Criteria for Adverse Events, and a probit
dose response model was created with maximum likelihood parameter fitting.
Results: This analysis includes a total of 89 brachial plexus maximum point dose (Dmax) values from both institutions. Among the 14 patients who developed brachial plexopathy, the most common complications were grade
2, comprising 7 patients. The median follow-up was 30 months (range 6.1–72.2) in the Karolinska dataset, and the
Indiana dataset had a median of 13 months (range 1–71). Both studies had a median range of 3 fractions, but in the
Indiana dataset, 9 patients were treated in 4 fractions, and the paper did not differentiate between the two, so our
analysis is considered to be in 3–4 fractions, one of the main limitations. The probit model showed that the risk of
brachial plexopathy with Dmax of 26 Gy in 3–4 fractions is 10%, and 50% with Dmax of 70 Gy in 3–4 fractions.
Conclusions: This analysis is only a preliminary result because more details are needed as well as additional comprehensive datasets from a much broader cross-section of clinical practices. When more institutions join the QUANTEC
and HyTEC methodology of reporting sufficient details to enable data pooling, our field will finally reach an improved
understanding of human dose tolerance.
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Department of Radiation Oncology, Geisinger Cancer Institute, 100 N
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Background
Stereotactic body radiation therapy (SBRT) is a treatment option increasingly used for patients with lung
cancer, including apical lung tumors, who are not surgical candidates. The main objective of the treatment is
to provide the most effective SBRT dose on the tumor
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with minimal effect on normal tissue while avoiding
post-radiation complications. Based on the tumor location (proximal of the brachial plexus), tumor size, dose,
and numerous other factors, a potentially severe adverse
effect after SBRT is radiation induced brachial plexopathy
(RIBP) [1, 2]. Onset of RIBP symptoms may occur from
months to years after the radiotherapy [3]. Brachial plexopathy, as defined in the Common Terminology Criteria
for Adverse Events (CTCAE) v.5 [4], may include muscle
weaknesses of the upper limbs, neuropathic pain, limitation of movement, paresthesia, and wasting. Understanding the tradeoffs between the benefits and risks in SBRT
dose and fractionation can provide clarity by considering
the range of severity in symptoms, from asymptomatic to
full loss of movement of the upper extremity.
In 1991, the Emami paper [5] recommended a 5% risk
in 5-year tolerance dose (TD 5/5) on the entire brachial
plexus to be 60 Gy in conventional fractionation, based
on expert opinion and on dose–response models [6]. Just
3 years later, the first clinical SBRT paper [7] included a
dose–response model [8] to guide clinical practice, and
a recent dose–response model for brachial plexus has
been published [2] by the same institution. After a quarter of a century of SBRT practice, other studies validating
these models are lacking and are needed to definitively
determine tolerance of brachial plexus to SBRT. North
American clinical trials for stereotactic ablative body
radiotherapy (SABR) began at Indiana University [9], and
the brachial plexus dose and toxicity outcome for each
patient in a cohort was published [1]. The datasets from
Indiana University and Karolinska Institute were pooled
in the current study and analyzed as recommended by
QUANTEC methodology [10, 11]. If this was standard
practice in radiation oncology, then our understanding of human dose tolerance of various normal tissues
to radiation would be vastly improved. Unfortunately,
these examples are the extreme rarity, to the degree that,
although a PubMed search of (SBRT OR SABR) AND
(spinal cord) returns more than 250 papers, the High
Dose per Fraction, Hypofractionated Treatment Effects
in the Clinic (HyTEC) [12] effort was only able to find
3 papers that provided full datasets with critical structure dose and toxicity outcome per patient for spinal
cord, which only represents about 1% of the published
literature.
If detailed reporting of the spinal cord is so rare, even
though it is among the most important critical structures
in the body, it will be even harder to accumulate sufficient data for other organs. Therefore, is it possible to
create comprehensive Emami-style dose tolerance limits
[5] for intricate structures such as brachial plexus? The
goal of the dose volume histogram (DVH) Risk Map [13]
is to provide a modernized graphical view of Emami-style
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unified low- and high-risk limits, along with a numerical
summary of the constraints and estimates of associated
risk. The aim of this paper is to summarize initial steps
towards creation of the DVH Risk Map for the brachial
plexus as an impetus to improve data reporting across
published literature for better understanding of tolerance
levels.

Methods
To identify brachial plexus dose tolerance after SBRT
based on dose–response models of clinical outcomes
data, the following 6 elements are needed: (1) dose to the
brachial plexus, (2) fractionation, (3) volume, (4) endpoint, (5) follow-up time, and (6) incidence of the endpoint occurring within the follow-up time [13]. These 6
items are needed per patient, or at least in enough detail
to stratify data into small groups of patients with similar
characteristics. A PubMed search for (brachial plexus)
AND (stereotactic OR SABR OR SBRT) was performed,
and 52 papers were found as of July 2020, but only two of
the studies came close to providing the needed information for all patients in a study.
The two datasets were comprised of patients treated (1)
at Indiana University and the Richard Roudebush Veterans Administration Medical Center from 1998 to 2007 [1]
as well as (2) the Karolinska Institute from 2008 to 2013
[2]. All patients in both studies were treated for apically
located lung tumors localized superior to the aortic arch.
A total of 89 patients (with 93 lesions) from both institutes received SBRT and were included in this analysis.
Physical dose without any biological conversions was
used in the graph of presented brachial plexus maximum
doses in the Indiana dataset, and the linear quadratic
(LQ) model [14, 15] as well as the universal survival curve
(USC) [16] were used to assess the data. In the Karolinska dataset, dose–response models were created using
both the LQ and USC models. The probit dose–response
model [17] was used in the Lindberg et al. [2] study, so
this model was also used in our pooled analysis for consistency. Brachial plexus maximum point dose (Dmax)
values were digitized from the source graphs [1, 2] with
the DVH Evaluator software [13], which then was used
to perform maximum likelihood parameter fitting [18] to
determine the values for the probit model [17], and confidence intervals were constructed using the profile likelihood method [19, 20].
All clinical data were collected from the patient records
and graded using the Common Terminology Criteria
for Adverse Events (CTCAE). Only toxicities of Grade
2 and greater in both studies were scored as complications. Indiana University used CTCAE version 3.0 [21]
with scoring of grade 1–4 while Karolinska used CTCAE
version 4.0 [22]. CTCAE version 3.0 focused more on
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the symptoms affecting activities of daily living while
version 4 stressed the severity of the symptoms. For the
purpose of inclusion, we have also included the Modified
Late Effects Normal Tissue—Subjective Objective Management Analytic (LENT-SOMA) scale [23, 24] to compare the brachial plexus adverse effects. The details of the
grading of toxicity are shown in Table 1. The following
variables were considered in the comparison of toxicity
rates: gender, age, histology, number and size of tumors,

dose of SBRT, number of fractions, and time to brachial
plexopathy from SBRT. The Fisher Exact Test was used to
assess significance among individuals with toxicity and
those without toxicity [25, 26].

Results
Patient characteristics, SBRT doses, and grading of radiation induced brachial plexopathy are compared in Table 2
for both studies. The median patient age was 72 and 73

Table 1 Endpoint definitions: brachial plexus toxicity grading scales
CTCAE Version 3.0 [21]
Grade 1 Asymptomatic brachial plexopathy

CTCAE Version 4.0 [22]

Modified LENT-SOMA scale [23]

Asymptomatic effects

Mild sensory deficits, no pain, no treatment
required

Grade 2 Symptomatic brachial plexopathy without inter- Moderate symptoms limiting ADL
fering with activities of daily living (ADL)

Moderate sensory deficits, tolerable pain, mild
arm weakness

Grade 3 Symptomatic brachial plexopathy and interfering with ADL

Severe symptoms limiting self care ADL Continuous paresthesia, with incomplete paresis,
pain medication required

Grade 4 Disabling brachial plexopathy

N/A

Complete paresis, excruciating pain, muscle
atrophy, regular pain medication required

CTCAE common terminology criteria for adverse events, LENT late effects normal tissues, SOMA subjective, objective, management, analytic, ADL activities of daily
living

Table 2 Apical lesion patient characteristics

Number of patients

Indiana University

Karolinska University

Total

37

52

89

Gender
Male

21

23

44

Female

16

29

45

Age at treatment, median (range)

73 (57–81)

72 (35–88)

Number of tumors

37

56

Primary lung cancer (NSCLC)

37

30a

67

Metastases

0

22

22

93

Tumors
Right

21

28

49

Left

16

28

44

Volume cc, median (range)

GTV 13 (1–113)

CTV 9.1 (0.10–74.5)

Follow-up months, median (range)

13 (1–71)

30 (6.1–72.2)

Total treatment dose (Gy), median (range)

57 (30–72)

Median 45 Gy in 3 fx
BED10 Range: 95–138 Gy

Median dose per fraction (Gy) (range)

19 (10–24)

15 (6–17)

Median number of fractions (range)

3 (3–4)

3 (3–10)

Number of patients with brachial plexopathy
Total

7

7

Grade 2

4

3

7

Grade 3

2

4

6

1

0

1

7 (6–23)

5.8 (0.7–13)

Grade 4
Brachial plexopathy development in months post-SBRT,
median (range)

NSCLC non-small cell lung cancer, GTV gross tumor volume, CTV clinical tumor volume, fx fractions; BED10 biological effective dose with α/β = 10 Gy
a

One patient with metastasis later on

14
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for Karolinska University and Indiana University, respectively. 93 tumors were treated in total with 22 patients
having metastases.
Dose, fractionation, and volume of the brachial plexus

At Indiana University, the median prescribed treatment dose was 57 Gy in 3–4 fractions and the maximum
brachial plexus dose ranged from 6 to 83 Gy (median,
26 Gy). The Indiana University dataset had 37 brachial plexus Dmax values (for 36 patients) that were all
included in the model. The paper did not report which
patients received 3 or 4 fractions, or volume information,
and these are the main limitations of the study [1]. Both
published datasets [1, 2] used biological conversions with
α/β = 3 Gy, thus the biological effective dose is denoted
as BED3. According to the linear quadratic model [14,
15], the 2 Gy per day equivalent EQD2 = 60 Gy Emami
brachial plexus limit [5] corresponds to B
 ED3 = 100 Gy.
In 3 fractions, LQ equates this to 26 Gy, which was equal
to the median brachial plexus Dmax of the 37 cases, and
this was initially used as a cutoff point of risk analysis,
finding the two-year Kaplan–Meier risk of 46% vs 8%
above and below this cutoff [1].
The Karolinska group used 45 Gy in 3 fractions for 80%
of the cases, therefore that also was the median prescription. One patient was treated with 60 Gy in 10 fractions,
six were treated with 56 Gy in 8 fractions, and the rest
were in 3–5 fractions. The authors performed analysis
with both USC and LQ models and found no major difference between the two for their data, so presented the
data in terms of BED3 with the LQ model. Brachial plexus
Dmax ranged from BED3 = 0.10–524 Gy, which we converted to 3-fraction equivalent dose since the median
number of fractions in both studies was 3. The Karolinska dataset presented model parameters for Dmax, in
addition to dose to hottest X cc (Dx) for D0.1cc, D1cc
and D3cc, but the group from Indiana University only
reported on Dmax. Therefore, the pooled model has no
volume information, and consists of maximum point
doses only.
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worsening to arm and hand wasting. This case corresponded to brachial plexus Dmax of 76 Gy. One patient
from Karolinska also noted signs of RIBP 13 months
post SBRT further progressing to total paralysis of the
arm, but was scored as grade 3 since CTCAE 4.0 is without grade 4 RIBP. Therefore, the LENT-SOMA scale is
a useful point of comparison in this regard as shown in
Table 1, because it does include a definition of grade 4.
It is also important to note that in the Karolinska
study, 13 patients underwent additional radiotherapy to
the lung ipsilateral to the tumor site that is not included
in the model in Fig. 1. Out of the 13, 10 of the patients
had very low additional brachial plexus dose, D
 max
BED3 ≤ 3.1 Gy. The remaining 3 had a prior conventional
dose of Dmax BED3 = 90–123 Gy with only 1 patient from
this subset developing RIBP. Therefore, for the Karolinska study, 6 out of 7 patients developed RIBP strictly only
from the SBRT.
Dose–response model and DVH Risk Map

Given the approximation of the 6 elements needed for a
dose–response model [13], and considering their limitations, caveats, and confounding factors as enumerated
above and described in the discussion, a pooled dose–
response model was created. According to the fitted probit model [17–20], the dose corresponding to 50% risk of
complications was 70.2 Gy (95% CI 55–116 Gy), and the
slope parameter at this dose was 0.49 (95% CI 0.35–0.74).

Endpoint, Follow‑up time, and estimated risk
of the endpoint occurring within the follow‑up time

Follow-up was longer in Karolinska with median
30 months (range 6.1–72.2) while Indiana had a median
of 13 months (range 1–71). Among the 89 patients
included in both studies, 14 of them developed CTCAE
grade 2 or higher RIBP, acknowledging the differences
among the endpoint definitions in Table 1. Among the
14, the most common complications were grade 2, comprising 7 patients. Only 1 patient from Indiana University was recorded with grade 4 disabling RIBP described
as shoulder ache progressing to paresthesia and further

Fig. 1 The probit model [17] of Grade 2–4 Brachial Plexopathy
shows the Dmax values of the Karolinska and Indiana University (IU)
datasets [1, 2] with red squares denoting the cases corresponding to
CTCAE grade 2 or higher adverse events (AE), blue dots representing
the cases without AE, and quartiles plotted as the four blue bars.
According to the model in 3–4 fractions, the risk of a brachial
plexopathy with the dose of 26 Gy is 10%, whereas the 25% and 50%
risk levels correspond to 47 and 70 Gy respectively
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The probit model and 95% confidence intervals are
depicted in Fig. 1 [17–20]. Significance was assessed via
the Fisher Exact Test [25, 26] split at the median dose of
the Indiana dataset (Dmax = 26 Gy), and at the median
dose of the combined dataset (Dmax = 27 Gy), yielding
p-values of 0.01 and 0.0035, respectively. The 5%, 10%,
and 25% risk levels were 13.7, 26, and 47 Gy, respectively,
in 3–4 fractions. Appendix Fig. 5 shows that for this dataset, probit and logistic models are within ± 1.6% of their
average, up to 60 Gy in 3–4 fractions, and diverge from
each other above this dose where the data is very sparse.
The connection between dose/volume, fractionation,
and incidence of complications for the endpoint of grade
2 or higher brachial plexopathy is summarized in the
form of a DVH Risk Map [13] in Fig. 2. This map includes
a graph of published dose constraints in the upper portion of the figure, as well as a numerical summary of
low- and high-risk constraints in the lower portion of
the figure, with the resultant estimates of risk from the
pooled model from Fig. 1. Appendix Fig. 4 shows how the
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5% and 50% risk levels at 5 years (TD 5/5 and TD 50/5) in
the Emami paper [5] were obtained from expert opinion
and models in the Burman paper [6]. Similarly, risk levels
in the DVH Risk Map in Fig. 2 are interpolated from the
dose–response model of Fig. 1. A more complete description of the DVH Risk Map may be found for several other
organs-at-risk in the literature [27–29].
The DVH Risk Map in Fig. 2 shows the number of fractions on the x-axis and the raw total physical dose without any BED conversion on the y-axis. Each of the five
panels specifies a dose/volume metric including dose
for the 50% and 10% volumes, as well as D3cc, D1cc,
and Dmax. Published dose constraints from Appendix
Table 3 are plotted as blue diamond marks on the map
(Fig. 2). These constraints were partitioned into lowand high-risk categories from among the more established limits, represented as the circled selected limits
with labels. The red X represents the dose at which a
published Adverse Event (AE) occurred, as may be seen
in Appendix Table 3. For visualization, a trendline of

Fig. 2 DVH Risk Map for brachial plexus. Note that NRG LU-002 protocol has adopted the Dmax = 26 Gy in 3 fraction constraint from Forquer 2009
[1], which we have designated as the low-risk limit for Dmax in 3 fractions. In the tabular portion of the figure, the limits that had already been
published are bold, and the rest are italicized. For the Dmax limits in 3–4 fractions, the estimated risk level interpolated from the model in Fig. 1 is
shown to the right of the dose constraint
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low- and high-risk are drawn as the dashed green and
solid red lines in this map. Although the partitioning is
somewhat arbitrary, this is approximately analogous to
the TD5/5 and TD 50/5 Emami limits for conventional
fractionation, but now customized to the published limits
in a more useful clinical range of practice. Based on the
pooled dataset, as may be seen from the tabular portion
of Fig. 2, the low-risk trend of brachial plexus Dmax in
3–4 fractions is about 10% risk and the high-risk trend is
about 15% risk.

Discussion
Bias and uncertainty can result from single institution
non-randomized heterogeneous mixtures of patients
with varying follow-up times and unknown censoring of competing risks. Throughout the past quarter
of a century, over a million patients have been treated
with radiosurgery on Gamma Knife alone [30], over a
million more patients have been treated with SBRT on
CyberKnife alone [31], and countless more have been
treated on stereotactically capable linear accelerators. No
excuse remains for there to be only two limited published
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datasets for an important critical structure like the brachial plexus. It is imperative that the field of radiation
oncology collects data more rigorously as highlighted by
the lessons of QUANTEC [10, 11] and as continues to
be emphasized by all the HyTEC papers [12, 32]. In the
meantime, it is important to glean as much information
as possible from the sparse datasets that do exist, and to
pool them into increasingly larger datasets [10]. A full deidentified database of 197 patients with dosimetric information and outcome for each patient was published more
than 100 years ago [33], showing that it is possible to
accomplish this without sophisticated algorithms (Fig. 3).
One of the first dose–response models was created more
than 90 years ago from clinical data by hand on graph
paper [34], even before the first electronic computer was
invented. With modern automated algorithms, there is
no excuse to not save and analyze the data in properly
designed studies with actuarial outcomes at specific time
points in multiple institutions with large cohorts of data.
The dose-tolerance numbers for conventional fractionation from the Emami paper were based on expert opinion
over 30 years ago, in terms of the radiation dose limits for

Fig. 3 Excerpt of an example de-identified published database from 1914, “Some Experiments in Standardization of Dosage” [33]. Although
precision is limited since this table pre-dates the definition of the rad by 4 decades [35] and was long before any of the modern grading systems
[4], nevertheless the sharing of fractionation, multiple parameters of dose, and outcome per patient as still recommended by HyTEC and QUANTEC
[10–12, 32] is truly remarkable, since this dataset of 197 cases is from more than 100 years ago

Kapitanova et al. Radiat Oncol

(2021) 16:98

1/3, 2/3 and 3/3 organ volume, with the probability of 5%
(TD 5/5) or 50% (TD 50/5) risks of complications within
a 5-year follow-up. The original paper did emphasize the
need for more research and available data. Two decades
later the ensuing accumulated published data was consolidated into QUANTEC [36] which was much more accurate owing to the growing body of cooperative trials and
institutional studies. However, the improved accuracy
of QUANTEC also came with increased complexity and
varied format of the limits, which is difficult to use in day
to day clinical work. The goal of the DVH Risk Map [13]
is to balance the convenience of a unified framework of
dose tolerance limits in low-risk and high-risk categories,
with the accuracy of dose–response modeling from all
the emerging published clinical data, particularly in the
setting of hypofractionated SBRT.
Brachial plexus dose tolerance for conventional fractionation has been studied [5, 37, 38] and contouring
guidelines are available [2, 39, 40]. The Emami limit for
brachial plexus of EQD2 = 60 Gy [5] corresponds to
26 Gy in 3 fractions, which is remarkably the same dose
limit as recommended in the Indiana study [1]. However,
the paradigm has transformed from allowing 100% organ
exposure at that dose in conventional fractionation [5],
now all the way down to the 0% volume at the same dose
for SBRT [1, 41].
About one third of the combined dataset had Dmax
values in excess of 10 Gy per fraction, where the LQ
model has been questioned [16]. For this reason the
Karolinska authors compared LQ to USC, and found no
major difference for this data [2]. The Indiana dataset was
published in terms of physical dose, which avoids questions regarding BED models, but is itself a major limitation of the pooled model since the fractionation was not
reported per patient.
Gender, age, histology, number and size of tumors,
dose of SBRT, number of fractions, and time to brachial
plexopathy from SBRT varied but were reasonably similar across studies as may be seen in Table 2. However,
neither study provided these values per patient, therefore
no multivariate analyses or subgroups of dose–response
models could be performed. The median length of patient
follow-up was more than twice as long in the Karolinska
study (30 vs 13 months), but at least the median followup in the Indiana University study was longer than the
median onset of brachial plexopathy in either study (7
and 5.8 months). Both studies included some patients
with less follow-up time than the latest reported complication in either study, so it is highly likely that a longer
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follow-up period would reveal at least somewhat higher
percentage of complications in either study.
Limitations of both studies include data based on a
small cohort of patients with limited follow-up. These
data may not reflect the full incidence of toxicity after
SBRT because many patients might not survive long
enough for toxicity to develop or may be lost to followup for a variety of reasons. Another limitation is the
usage of re-irradiation for some of the Karolinska cases,
although this only caused one of the complications, so
insufficient data were available to construct a model that
could account for re-irradiation tolerance. The Karolinska authors reported distance and overlap of the brachial
plexus to the tumor, but the Indiana University authors
did not, so this factor was not included in the pooled
analysis. Differences in grading of complications was
acknowledged, which may contribute to inaccurate causal
analysis. Half of the complications were grade 2, and only
one potentially grade 4 paresis was reported in each of
the two studies. However, the studies did not indicate the
specific grade for each Dmax value of the whole dataset,
so separate models for each grade cannot be created, as
was done in a brain dose tolerance study [42]. Furthermore, as noted in Table 1, the grading scales vary especially for the higher-grade events. A risk of 10% is higher
than ideal for brachial plexus, but until the grade of each
patient is reported in a consistent scale, clinicians must
use their own judgement when interpreting the results.

Conclusions
For lung cancers near the apical region, brachial plexopathy is a major concern for high-dose radiation therapy.
Based on our analysis of published data, the risk of grade
2 or higher brachial plexus toxicity after SBRT is approximately 5%, 10%, and 50% at 13.7, 26, and 70 Gy, respectively, in 3–4 fractions, but the risk of grade 3 or 4 toxicity
remains unknown. This paper is not intended to be a final
answer, but rather an appreciation of recent efforts and
a plea for more data: it is commendable that the Indiana
and Karolinska authors published the data that enabled
this pooled model, as recommended by QUANTEC and
HyTEC. When more institutions join the QUANTEC
and HyTEC methodology of reporting sufficient details
to enable data pooling, our field will finally reach an
improved understanding of human dose tolerance.

Appendix
See Figs. 4, 5 and Table 3.
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Fig. 4 Emami paper [5] examples from expert opinion and Burman [6] models. Arrows depict how the 5% risk levels were interpolated from the
Burman [6] model for the Emami [5] table of dose tolerance. Dots on the graph depict the TD 5/5 and TD 50/5 tolerance doses, which correspond
to the values in the table. Kidney is a parallel structure so it is intuitive that the 5% risk level for 1/3 and 3/3 volumes were very different, whereas
brachial plexus is predominantly a serial structure, so the 5% risk levels were fairly similar for conventional fractionation regardless of volume.
However, Table 3 of the Karolinska study [2] shows a 50% reduction in tolerance of brachial plexus D3cc as compared to the maximum point dose
(Dmax), therefore volume effects may be more important for SBRT. In the Emami paper [5], for both kidney and brachial plexus the TD5/5 and
TD50/5 limits were in close agreement with the models. However, for other structures such as Bladder there was more reliance on expert opinion,
as can be observed by the location of the TD 5/5 and TD 50/5 dots in the Burman paper [6], in relation to the modeled curves

Fig. 5 Comparison of logistic [74] and probit [17] in Schultheiss et al.
[75] showed that for some datasets these two models may differ by less
than 1% over their entire range. For this dataset as shown above, the two
models differ by no more than ± 1.6% from their average, up to 60 Gy in
3–4 fractions, but diverge at doses above that where the data is sparse.
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The following form of the probit model [17] was used
in the manuscript:
t
1
2
∫ e−x /2 dx
NTCPprobit = √
2π −∞

(1)

where
TD50
is
the
50%
risk
level,
t = (Dmax − TD50 )/(m × TD50 ), and m is the normalized slope.
The following form of the logistic model [74] was
used in Fig. 5 for comparison:

NTCPlogistic = 1/(1 + (TD50 /Dmax )∧ (4 ∗ g50 )), (2)
where TD50 is the 50% risk level and g50 is the slope
parameter.
Acknowledgements
The authors would like to thank Dr. Paula Lim, MD for working on the
manuscript.
Authors’ contributions
All authors contributed to the study concept, drafting and editing the manuscript, and approved the final version for publication. IK, SB, PL, SD, and JG
performed the literature review. RJG analyzed the data and created the dose–
response model. IK, SB, PL and SD created the first 10 revisions of the paper.
EJK, RAR, KMF, RJG, CJS, JG, BE, AM provided initial clinical input after the 10th
revision. AM, and BE are the senior authors of the work and made major edits
especially toward completion of the work. All authors read and approved the
final manuscript.
Funding
None.
Availability of data and materials
The datasets generated during and/or analysed during the current study are
available in the published literature.

Declarations
Ethics approval and consent to participates
Not applicable, since data was existent in the literature.
Consent for publication
Not applicable, since the manuscript does not contain data from any individual person.
Competing interests
IK, SB, SD, EJK, RAR, KMF, RJG, CJS, BE, AM: None. JG: Grants from Accuray,
grants from NovoCure, outside the submitted work; In addition, Dr. Grimm has
a patent DVH Evaluator issued.
Author details
1
Department of Psychiatry, Mount Sinai St. Luke’s Hospital, New York, NY,
USA. 2 Department of Pediatric Nephrology, Weill Cornell Medicine, New
York, NY, USA. 3 Sackler School of Medicine, Tel Aviv University, New York, NY,
USA. 4 Department of Radiation Oncology, Geisinger Cancer Institute, 100 N
Academy Ave, Danville, PA 17822, USA. 5 Department of Radiation Oncology,
Thomas Jefferson Hospital, Philadelphia, PA, USA. 6 Department of Medical
Imaging and Radiation Sciences, Thomas Jefferson University, Philadelphia, PA,
USA. 7 Department of Radiation Oncology, Loyola University Medical Center,
Chicago, IL, USA.
Received: 23 October 2020 Accepted: 19 May 2021

References
1. Forquer JA, Fakiris AJ, Timmerman RD, Lo SS, Perkins SM, McGarry RC,
Johnstone PA. Brachial plexopathy from stereotactic body radiotherapy in
early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother
Oncol. 2009;93(3):408–13.
2. Lindberg K, Grozman V, Lindberg S, Onjukka E, Lax I, Lewensohn R, Wersäll
P. Radiation-induced brachial plexus toxicity after SBRT of apically located
lung lesions. Acta Oncol. 2019;58(8):1178–86.
3. Fathers E, Thrush D, Huson SM, Norman A. Radiation-induced brachial
plexopathy in women treated for carcinoma of the breast. Clin Rehabil.
2002;16(2):160–5. https://doi.org/10.1191/0269215502cr470oa.
4. National Cancer Institute. Common Terminology Criteria for Adverse
Events v5.0. November 27, 2017. Accessed https://ctep.cancer.gov/proto
colDevelopment/electronic_applications/ctc.htm.
5. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B,
Solin LJ, Wesson M. Tolerance of normal tissue to therapeutic irradiation.
Int J Radiat Oncol Biol Phys. 1991;21(1):109–22.
6. Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue
tolerance data to an analytic function. Int J Radiat Oncol Biol Phys.
1991;21(1):123–35.
7. Lax I, Blomgren H, Näslund I, Svanström R. Stereotactic radiotherapy of malignancies in the abdomen. Methodol Asp Acta Oncol.
1994;33(6):677–83.
8. Lawrence TS, Ten Haken RK, Kessler ML, Robertson JM, Lyman JT, Lavigne
ML, Brown MB, DuRoss DJ, Andrews JC, Ensminger WD, et al. The use of
3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol
Biol Phys. 1992;23(4):781–8.
9. Timmerman R, Papiez L, McGarry R, Likes L, DesRosiers C, Frost S,
Williams M. Extracranial stereotactic radioablation: results of a phase I
study in medically inoperable stage I non-small cell lung cancer. Chest.
2003;124(5):1946–55.
10. Deasy JO, Bentzen SM, Jackson A, Ten Haken RK, Yorke ED, Constine LS,
Sharma A, Marks LB. Improving normal tissue complication probability
models: the need to adopt a “data-pooling” culture. Int J Radiat Oncol Biol
Phys. 2010;76(3 Suppl):S151–4.
11. Jackson A, Marks LB, Bentzen SM, Eisbruch A, Yorke ED, Ten Haken RK,
Constine LS, Deasy JO. The lessons of QUANTEC: recommendations for
reporting and gathering data on dose-volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S155–60.
12. Sahgal A, Chang JH, Ma L, Marks LB, Milano MT, Medin P, Niemierko A,
Soltys SG, Tomé WA, Wong CS, Yorke E, Grimm J, Jackson J. Spinal cord
dose tolerance to stereotactic body radiotherapy. Int J Radiat Oncol Biol
Phys. 2021;110(1):124–36.
13. Asbell SO, Grimm J, Xue J, Chew MS, LaCouture TL. Introduction and clinical overview of the DVH Risk Map. Semin Radiat Oncol. 2016;26(2):89–96.
14. Fowler JF, Stern BE. Dose-rate factors in integral dose estimations [letter].
Br J Radiol. 1958;31:316.
15. Fowler JF. 21 years of biologically effective dose. Br J Radiol.
2010;83(991):554–68.
16. Park C, Papiez L, Zhang S, Story M, Timmerman RD. Universal survival
curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys.
2008;70(3):847–52.
17. Herbert D. The assessment of the clinical significance of non-compliance
with prescribed schedules of irradiation. Int J Radiat Oncol Biol Phys.
1977;2(7–8):763–72.
18. Jackson A, Ten Haken RK, Robertson JM, Kessler ML, Kutcher GJ, Lawrence TS. Analysis of clinical complication data for radiation hepatitis
using a parallel architecture model. Int J Radiat Oncol Biol Phys.
1995;31(4):883–91.
19. Cox DR, Snell EJ. Analysis of binary data. 2nd ed. London: CRC; 1989.
20. Levegrün S, Jackson A, Zelefsky MJ, Skwarchuk MW, Venkatraman ES,
Schlegel W, Fuks Z, Leibel SA, Ling CC. Fitting tumor control probability models to biopsy outcome after three-dimensional conformal
radiation therapy of prostate cancer: pitfalls in deducing radiobiologic
parameters for tumors from clinical data. Int J Radiat Oncol Biol Phys.
2001;51:1064–80.
21. Cancer Therapy Evaluation Program, Common Terminology Criteria for
Adverse Events, Version3.0, DCTD, NCI, NIH, DHHS, March 31, 2003. http://
ctep.cancer.gov. Publish date 9 Aug 2006.

Kapitanova et al. Radiat Oncol

(2021) 16:98

22. Cancer Therapy Evaluation Program, Common Terminology Criteria for
Adverse Events, Version4 .0, DCTD, NCI, NIH, DHHS, December 23, 2009.
http://ctep.cancer.gov. Publish date 28 May 2009.
23. LENT SOMA scales for all anatomic sites. Int J Radiat Oncol Biol Phys.
1995;31:1049–1091.
24. Fehlauer F, Tribius S, Holler U, et al. Long-term radiation sequelae after
breast-conserving therapy in women with early-stage breast cancer: an
observational study using the LENT-SOMA scoring system. Int J Radiat
Oncol Biol Phys. 2003;55:651–8.
25. Fisher RA. On the interpretation of χ 2 from contingency tables, and the
calculation of P. J R Stat Soc. 1922;85:87.
26. Cox BW, Jackson A, Hunt M, Bilsky M, Yamada Y. Esophageal toxicity from
high-dose, single-fraction paraspinal stereotactic radiosurgery. Int J
Radiat Oncol Biol Phys. 2012;83(5):e661–7.
27. Kimsey F, McKay J, Gefter J, Milano MT, Moiseenko V, Grimm J, Berg R.
Dose-response model for chest wall tolerance of stereotactic body radiation therapy. Semin Radiat Oncol. 2016;26(2):129–34.
28. Xue J, Kubicek G, Patel A, Goldsmith B, Asbell SO, LaCouture TA. Validity of
current stereotactic body radiation therapy dose constraints for aorta and
major vessels. Semin Radiat Oncol. 2016;26(2):135–9.
29. Goldsmith C, Price P, Cross T, Loughlin S, Cowley I, Plowman N. Dosevolume histogram analysis of stereotactic body radiotherapy treatment
of pancreatic cancer: a focus on duodenal dose constraints. Semin Radiat
Oncol. 2016;26(2):149–56.
30. Kondziolka D. Current and novel practice of stereotactic radiosurgery. J
Neurosurg. 2019;130(6):1789–98.
31. Depp JG. Personal Communication, Founding President and CEO,
Accuray Incorporated. Accessed http://quantum.site.nfoservers.com/
Joe/.
32. Mahadevan A, Moningi S, Grimm J, Li XA, Forster KM, Palta M, Prior P,
Goodman KA, Narang A, Heron DE, Urbanic Lo SS, J, Herman JM. Maximizing Tumor Control and limiting complications with SBRT for Pancreatic
Cancer. Int J Radiat Oncol Biol Phys. 2021;110(1):206–16.
33. Holmes G. Some experiments in standardization of dosage for Roentgen
therapeutics. Am J Röentgenol. 1914;1:298–302.
34. Quimby EH, Pack GT. The skin erythema for combinations of gamma and
Roentgen rays. Radiology 1929;13:306 [Read by Mrs. Edith H. Quimby
before the Radiological Society of North America at the fourteenth
annual meeting, at Chicago, 3–7 Dec 1928].
35. Taylor LS. History of the international commission on radiological units
and measurements (ICRU). Health Phys. 1958;1(3):306–14.
36. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch
A, Bentzen SM, Nam J, Deasy JO. Use of normal tissue complication
probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76(3
Suppl):S10–9.
37. Svensson H, Westling P, Larsson LG. Radiation-induced lesions of the brachial plexus correlated to the dose-time-fraction schedule. Acta Radiol
Ther Phys Biol. 1975;14(3):228–38.
38. Yan M, Kong W, Kerr A, Brundage M. The radiation dose tolerance of the
brachial plexus: A systematic review and meta-analysis. Clin Transl Radiat
Oncol. 2019;18:23–31.
39. Kong FM, Ritter T, Quint DJ, Senan S, Gaspar LE, Komaki RU, Hurkmans
CW, Timmerman R, Bezjak A, Bradley JD, Movsas B, Marsh L, Okunieff P,
Choy H, Curran WJ Jr. Consideration of dose limits for organs at risk of
thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. Int J Radiat Oncol Biol Phys.
2011;81(5):1442–57.
40. Li CH, Wu VW, Chiu G. A dosimetric evaluation on applying RTOG-based
and CT/MRI-based delineation methods to brachial plexus in radiotherapy of nasopharyngeal carcinoma treated with helical tomotherapy. Br J
Radiol. 2019;92(1102):20170881.
41. Ma TM, Emami B, Grimm J, Xue J, Asbell SO, Kubicek GJ, Lanciano R, Welsh
JS, Peng L, Gui C, Das IJ, Goldman HW, Brady LW, Redmond KJ, Kleinberg
LR. Volume effects in radiosurgical spinal cord dose tolerance: how small
is too small? J Radiat Oncol. 2019;8:53–61.
42. Peng L, Grimm J, Gui C, Shen CJ, Redmond KJ, Sloan L, Hazell S, Moore JA,
Huang E, Spoleti N, Laub W, Quon H, Bettegowda C, Lim M, Kleinberg LR.
Updated risk models demonstrate low risk of symptomatic radionecrosis
following stereotactic radiosurgery for brain metastases in the modern
era. Surg Neurol Int. 2019;10:32.

Page 12 of 13

43. Ryu S, Gerszten P, Yin F, Timmerman R, Dicker A, Movsas B, Wang M. Phase
II/III study of image-guided radiosurgery/SBRT for localized spine metastasis. Radiation Therapy Oncology Group 0631. Accessed http://www.
rtog.org.
44. Ryu S, Pugh SL, Gerszten PC, Yin FF, Timmerman RD, Hitchcock YJ, Movsas
B, Kanner AA, Berk LB, Followill DS, Kachnic LA. RTOG 0631 phase 2/3
study of image guided stereotactic radiosurgery for localized (1–3) spine
metastases: phase 2 results. Pract Radiat Oncol. 2014;4(2):76–81.
45. Videtic G, Singh A, Chang J, Le Q, Parker W, Olivier K, Schild S, Bae K. A
randomized phase II study comparing 2 stereotactic body radiation
therapy (SBRT) schedules for medically inoperable patients with stage I
peripheral non-small cell lung cancer. Radiation Therapy Oncology Group
0915. Accessed at http://www.rtog.org.
46. Benedict S, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, Keall
P, Lovelock M, Meeks S, Papiez L, Purdie T, Sadagopan R, Schell MC, Salter
B, Schlesinger DJ, Shiu AS, Solberg T, Song DY, Stieber V, Timmerman R,
Tomé WA, Verellen D, Wang L, Yin FF. Stereotactic body radiation therapy:
the report of AAPM Task Group 101. Med Phys. 2010;37(8):4078–101.
47. Timmerman RD. An overview of hypofractionation and introduction
to this issue of seminars in radiation oncology. Semin Radiat Oncol.
2008;18:215–22.
48. Whyte RI, Crownover R, Murphy MJ, Martin DP, Rice TW, DeCamp MM
Jr, Rodebaugh R, Weinhous MS, Le QT. Stereotactic radiosurgery for
lung tumors: preliminary report of a phase I trial. Ann Thorac Surg.
2003;75(4):1097–101.
49. Le QT, Loo BW, Ho A, Cotrutz C, Koong AC, Wakelee H, Kee ST, Constantinescu D, Whyte RI, Donington J. Results of a phase I dose-escalation
study using single-fraction stereotactic radiotherapy for lung tumors. J
Thorac Oncol. 2006;1(8):802–9.
50. Pennathur A, Luketich JD, Burton S, Abbas G, Heron DE, Fernando HC,
Gooding WE, Ozhasoglu C, Ireland J, Landreneau RJ, Christie NA. Stereotactic radiosurgery for the treatment of lung neoplasm: initial experience.
Ann Thorac Surg. 2007;83(5):1820–4 (discussion 1824–5).
51. Fernando H, Meyers B, Timmerman R, et al. RTOG 1021 A randomized
phase III study of sublobar resection (+/- brachytherapy) versus stereotactic body radiation therapy in high risk patients with stage I non-small
cell lung cancer (NSCLC).
52. Mutter RW, Liu F, Abreu A, Yorke E, Jackson A, Rosenzweig KE. Dosevolume parameters predict for the development of chest wall pain after
stereotactic body radiation for lung cancer. Int J Radiat Oncol Biol Phys.
2012;82(5):1783–90.
53. Milano MT, Constine LS, Okunieff P. Normal tissue toxicity after small field
hypofractionated stereotactic body radiation. Radiat Oncol. 2008;3:36.
54. Timmerman RD, Pass H, Galvin J, Edelman MJ, Gore E, Kong FM. A phase
II trial of stereotactic body radiation therapy (SBRT) in the treatment of
patients with operable stage I/II non-small cell lung cancer. Radiation
Therapy Oncology Group 0618. Accessed http://www.rtog.org.
55. Chang BK, Timmerman RD. Stereotactic body radiation therapy: a comprehensive review. Am J Clin Oncol. 2007;30:637–44.
56. Sinha B, McGarry RC. Stereotactic body radiotherapy for bilateral primary
lung cancers: the Indiana University experience. Int J Radiat Oncol Biol
Phys. 2006;66:1120–4.
57. Mould RF, Schulz RA, Bucholz RD, Gagnon GJ, Gerszten PC, Kresl JJ,
Levendag PC, Schulz RA, et al. Robotic Radiosurgery, vol. 1. Sunnyvale:
Cyberknife Society Press; 2005.
58. Urschel HC, Kresl JJ, Luketich JD, Papiez L, Timmerman RD, Schulz RA.
Treating tumors that move with respiration. Berlin: Springer; 2007.
59. Roth J, Chang J, Komaki R, Kresl J. International randomized study to
compare CyberKnifeR stereotactic radiotherapy with surgical resection in
stage I non-small cell lung cancer (STARS). Accessed http://clinicaltrials.
gov.
60. Dunlap NE, Cai J, Biedermann GB, Yang W, Benedict SH, Sheng K, Schefter
TE, Kavanagh BD, Larner JM. Chest wall volume receiving >30 Gy predicts
risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2010;76(3):796–801.
61. Schefter T, Kavanagh B, Raben D, Kane M, Chen C, Stuhr K, et al. A phase I/
II trial of Stereotactic body radiation therapy (SBRT) for lung metastases:
Initial report of dose escalation and early toxicity. Int J Radiat Oncol Biol
Phys. 2006;60:S120–7.
62. Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA,
Pugh TJ, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial

Kapitanova et al. Radiat Oncol

63.

64.
65.

66.

67.

68.

69.

(2021) 16:98

of stereotactic body radiation therapy for lung metastases. J Clin Oncol.
2009;27(10):1579–84.
Bradley JD, El Naqa I, Drzymala RE, Trovo M, Jones G, Denning MD.
Stereotactic body radiation therapy for early-stage non-small-cell lung
cancer: the pattern of failure is distant. Int J Radiat Oncol Biol Phys.
2010;77(4):1146–50.
Wulf J, Hadinger U, Oppitz U, Thiele W, Ness-Dourdoumas R, Flentje M.
Stereotactic radiotherapy of targets in the lung and liver. Strahlenther
Onkol. 2001;177(645):55.
van der Voort van Zyp NC, Prévost JB, Hoogeman MS, Praag J, van der
Holt B, Levendag PC, van Klaveren RJ, Pattynama P, Nuyttens JJ. Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung
cancer: clinical outcome. Radiother Oncol. 2009;91(3):296–300.
Chang JY, Balter PA, Dong L, Yang Q, Liao Z, Jeter M, Bucci MK, McAleer
MF, Mehran RJ, Roth JA, Komaki R. Stereotactic body radiation therapy in
centrally and superiorly located stage I or isolated recurrent non-smallcell lung cancer. Int J Radiat Oncol Biol Phys. 2008;72:967–71.
Chang JY, Bezjak A, Mornex F, IASLC Advanced Radiation Technology
Committee. Stereotactic ablative radiotherapy for centrally located early
stage non-small-cell lung cancer: what we have learned. J Thorac Oncol.
2015;10(4):577–85.
Chang JY, Li QQ, Xu QY, Allen PK, Rebueno N, Gomez DR, Balter P, Komaki
R, Mehran R, Swisher SG, Roth JA. Stereotactic ablative radiation therapy
for centrally located early stage or isolated parenchymal recurrences of
non-small cell lung cancer: how to fly in a “no fly zone.” Int J Radiat Oncol
Biol Phys. 2014;88(5):1120–8.
Mangona VS, Aneese AM, Marina O, Hymas RV, Ionascu D, Robertson JM,
Gallardo LJ, Grills IS. Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis. Int J
Radiat Oncol Biol Phys. 2015;91(1):124–32.

Page 13 of 13

70. Takeda A, Kunieda E, Sanuki N, Ohashi T, Oku Y, Sudo Y, Iwashita H, Ooka
Y, Aoki Y, Shigematsu N, Kubo A. Dose distribution analysis in stereotactic
body radiotherapy using dynamic conformal multiple arc therapy. Int J
Radiat Oncol Biol Phys. 2009;74(2):363–9.
71. Bezhak A, Bradley J, Gaspar L, Timmerman R, Papiez L, Gore E, Kong F, Bae
K, Normolle, D. Seamless phase I/II study of stereotactic lung radiotherapy
(SBRT) for early stage, centrally located, non-small cell lung cancer
(NSCLC) in medically inoperable patients. Radiation Therapy Oncology
Group 0813. Accessed http://www.rtog.org.
72. Nuyttens JJ, Moiseenko V, McLaughlin M, Jain S, Herbert S, Grimm J.
Esophageal dose tolerance in patients treated with stereotactic body
radiation therapy. Semin Radiat Oncol. 2016;26(2):120–8.
73. Onimaru R, Shirato H, Shimizu S, Kitamura K, Xu B, Fukumoto S, Chang
TC, Fujita K, Oita M, Miyasaka K, Nishimura M, Dosaka-Akita H. Tolerance
of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol
Phys. 2003;56(1):126–35.
74. Fischer DB, Fischer JJ. Dose response relationships in radiotherapy:
applications of logistic regression models. Int J Radiat Oncol Biol Phys.
1977;2(7–8):773–81.
75. Schultheiss TE, Orton CG, Peck RA. Models in radiotherapy: volume
effects. Med Phys. 1983;10(4):410–5.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research ? Choose BMC and benefit from:

• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year
At BMC, research is always in progress.
Learn more biomedcentral.com/submissions

